CoChat

Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 8 of the 28 sources its claims cite were checked for support.

Abstract

Objectives: Compare the safety of antiepileptic drugs (AEDs) on neurodevelopment of infants/children exposed in utero or during breast feeding. Design and setting: Systematic review and Bayesian random-effects network meta-analysis (NMA). MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched until 27 April 2017. Screening, data abstraction and quality appraisal were completed in duplicate by independent reviewers. Participants: 29 cohort studies including 5100 infants/children. Interventions: Monotherapy and polytherapy AEDs including first-generation (carbamazepine, clobazam, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproate) and newer-generation (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin) AEDs. Epileptic women who did not receive AEDs during pregnancy or breast feeding served as the control group. Primary and secondary outcome measures: Cognitive developmental delay and autism/dyspraxia were primary outcomes. Attention-deficit hyperactivity disorder, language delay, neonatal seizures, psychomotor developmental delay and social impairment were secondary outcomes. Results: The NMA on cognitive developmental delay (11 cohort studies, 933 children, 18 treatments) suggested that among all AEDs only valproate was statistically significantly associated with more children experiencing cognitive developmental delay compared with control (OR=7.40, 95% credible interval (CrI) 3.00 to 18.46). The NMA on autism (5 cohort studies, 2551 children, 12 treatments) suggested that oxcarbazepine (OR 13.51, CrI 1.28 to 221.40), valproate (OR 17.29, 95% CrI 2.40 to 217.60), lamotrigine (OR 8.88, CrI 1.28 to 112.00) and lamotrigine+valproate (OR 132.70, CrI 7.41 to 3851.00) were associated with significantly greater odds of developing autism compared with control. The NMA on psychomotor developmental delay (11 cohort studies, 1145 children, 18 treatments) found that valproate (OR 4.16, CrI 2.04 to 8.75) and carbamazepine+phenobarbital+valproate (OR 19.12, CrI 1.49 to 337.50) were associated with significantly greater odds of psychomotor delay compared with control. Conclusions: Valproate alone or combined with another AED is associated with the greatest odds of adverse neurodevelopmental outcomes compared with control. Oxcarbazepine and lamotrigine were associated with increased occurrence of autism. Counselling is advised for women considering pregnancy to tailor the safest regimen. Trial registration number: PROSPERO database (CRD42014008925).

Overview

CoChat Summary

TL;DR

This systematic review and Bayesian network meta-analysis of 29 cohort studies (5100 children) found that valproate alone or combined with another AED was associated with the greatest odds of adverse neurodevelopmental outcomes. Oxcarbazepine and lamotrigine were also associated with increased autism/dyspraxia.

Key findings

  • Cognitive developmental delay NMA (11 cohort studies, 933 children, 18 treatments): only valproate was significantly associated with more children experiencing cognitive developmental delay versus control (OR 7.40, 95% CrI 3.00 to 18.46).
  • Autism/dyspraxia NMA (5 cohort studies, 2551 children, 12 treatments): oxcarbazepine (OR 13.51, CrI 1.28 to 221.40), valproate (OR 17.29, 95% CrI 2.40 to 217.60), lamotrigine (OR 8.88, CrI 1.28 to 112.00) and lamotrigine+valproate (OR 132.70, CrI 7.41 to 3851.00) were associated with significantly greater odds of autism/dyspraxia versus control.
  • Psychomotor developmental delay NMA (11 cohort studies, 1145 children, 18 treatments): valproate (OR 4.16, CrI 2.04 to 8.75) and carbamazepine+phenobarbital+valproate (OR 19.12, CrI 1.49 to 337.50) were associated with significantly greater odds versus control.
  • Language delay NMA (5 cohort studies, 509 children, 5 treatments): valproate was the only treatment significantly associated with increased odds (OR 7.95, 95% CrI 1.50 to 49.13). ADHD NMA (5 cohort studies, 816 children, 7 treatments) found no treatment comparisons reached statistical significance.

Methods

  • Systematic review and Bayesian random-effects network meta-analysis; MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials searched until 27 April 2017; screening, data abstraction and quality appraisal completed in duplicate; registered with PROSPERO (CRD42014008925).
  • Included 29 cohort studies (5100 infants/children) of mothers consuming AEDs during pregnancy and/or breastfeeding; monotherapy and polytherapy first-generation and newer-generation AEDs were eligible; control was epileptic women who did not receive AEDs; primary outcomes were cognitive developmental delay and autism/dyspraxia, with secondary outcomes including ADHD, language delay, neonatal seizures, psychomotor developmental delay and social impairment.
  • Used ORs for dichotomous outcomes, hierarchical meta-analysis and NMA models in a Bayesian framework (OpenBUGS), random-effects models, transitivity and consistency assessments, network meta-regression and sensitivity analyses, and SUCRA rankings.

Limitations

  • Stated in the paper: drug dosages could not be accounted for, and different dosages of the same AED were assumed equally effective; when a study reported multiple dosages for the same treatment, data were combined.
  • Stated in the paper: several polytherapies had high SUCRA estimates but very wide credible intervals due to small numbers of studies and underpowered sample sizes; ranking probabilities may be biased toward treatments with the smallest number of studies.
  • Stated in the paper: no RCT evidence was available, so conclusions were based on observational studies only, with inherent confounding and shortcomings; important effect modifiers were often unreported (eg, family history of autism, ADHD, maternal IQ, severity of epilepsy), and subgroup analysis by exposure type (breastfeeding vs in utero) could not be conducted because 22 studies did not report breastfeeding exposure. Evident from the text: many NMAs included small numbers of studies/children, credible intervals were wide, and methodological quality was imbalanced across treatment comparisons.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2017-017248

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study flow diagram.
Figure 1 Study flow diagram.CC BY-NC · PubMed Central
Figure 2 Forest plots for cognitive developmental delay, autism/dyspraxia, psychomotor developmental delay, language delay and attention-deficit hyperactivity disorder outcome. carbam, carbamazepine; ethos, ethosuximide; gabap, gabapentin; lamot, lamotrigine; levet, levetiracetam; pheno, phenobarbital; pheny, phenytoin; PrI, predictive interval; primid, primidone; SUCRA, surface under the cumulative ranking; topir, topiramate; valpro, valproate.
Figure 2 Forest plots for cognitive developmental delay, autism/dyspraxia, psychomotor developmental delay, language delay and attention-deficit hyperactivity disorder outcome. carbam, carbamazepine; ethos, ethosuximide; gabap, gabapentin; lamot, lamotrigine; levet, levetiracetam; pheno, phenobarbital; pheny, phenytoin; PrI, predictive interval; primid, primidone; SUCRA, surface under the cumulative ranking; topir, topiramate; valpro, valproate.CC BY-NC · PubMed Central
Figure 3 Network diagrams for cognitive developmental delay, autism/dyspraxia, psychomotor developmental delay, language delay and attention-deficit hyperactivity disorder outcomes. Each treatment node is weighted according to the number of patients that have received the particular treatment, and each edge is weighted according to the number of studies comparing the treatments it connects. carbam, carbamazepine; clobaz, clobazam; clonaz, clonazepam; ethos, ethosuximide; gabap, gabapentin; lamot, lamotrigine; levet, levetiracetam; oxcar, oxcarbazepine; pheno, phenobarbital; pheny, phenytoin; primid, primidone; topir, topiramate; valpro, valproate; vigab, vigabatrin.
Figure 3 Network diagrams for cognitive developmental delay, autism/dyspraxia, psychomotor developmental delay, language delay and attention-deficit hyperactivity disorder outcomes. Each treatment node is weighted according to the number of patients that have received the particular treatment, and each edge is weighted according to the number of studies comparing the treatments it connects. carbam, carbamazepine; clobaz, clobazam; clonaz, clonazepam; ethos, ethosuximide; gabap, gabapentin; lamot, lamotrigine; levet, levetiracetam; oxcar, oxcarbazepine; pheno, phenobarbital; pheny, phenytoin; primid, primidone; topir, topiramate; valpro, valproate; vigab, vigabatrin.CC BY-NC · PubMed Central

Verification

Claims the paper makes

5 Valid · 0 Not valid · 13 Not checked · 67 Own results and interpretations

40 more claims

Create a free account to see all 85 claims and to verify the 20 references still open.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 24

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 50 references

Research works printed but not linked: 2

  1. Bromley R , Baxter N , Calderbank R , et al . A comprehensive review of the language abilities of children exposed to valproate or carbamazepine in utero. Texas: American Epilepsy Society, 2010.
  2. Gogatishvili N , Ediberidze T , Lomidze G , et al . Cognitive outcomes of children with fetal antiepileptic drug exposure at the age of 3-6 years-preliminary data. 1st 624 Congress of the European Academy of Neurology. Berlin: European Journal of Neurology, 2015:p.329.

Cited by

See all 222

Metadata

Authors
Veroniki, A. A., Rios, P., Cogo, E., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., Hemmelgarn, B. R., Yazdi, F., D'Souza, J., MacDonald, H., & Tricco, A. C.
Affiliations
  • St. Michael's Hospital (CA)
  • University of Toronto (CA)
  • University of Ottawa (CA)
  • University of Calgary (CA)
Corresponding author
Tricco, Andrea C
Venue
BMJ Open
Publisher
BMJ
Published
2017-07
Volume
7
Issue
7
Pages
e017248
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2738349700
Cited by
222
References
50
Citations by year
2026: 7 · 2025: 22 · 2024: 22 · 2023: 14 · 2022: 41 · 2021: 29 · 2020: 47 · 2019: 26 · 2018: 12 · 2017: 1
FWCI
4.41
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • CIHR/DSEN New Investigator Award in Knowledge Synthesis
  • Tier 1 Canada Research Chair in Knowledge Translation
  • Tier 2 Canada Research Chair in Knowledge Synthesis
  • Canadian Institutes for Health Research/Drug Safety and Effectiveness Network
  • Banting Postdoctoral Fellowship Program from the CIHR
  • Alberta Heritage Foundation for Medical Research
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Fetal and Pediatric Neurological Disorders
Keywords
antiepileptic drugs, prenatal drug exposure, breastfeeding, developmental neurotoxicity, autism spectrum disorder, cognitive delay, valproic acid, lamotrigine, oxcarbazepine, attention deficit hyperactivity disorder, neonatal seizures, epilepsy in pregnancy, drug safety comparison
MeSH terms
Lamotrigine, Oxcarbazepine, Anticonvulsants, Autistic Disorder, Bayes Theorem, Breast Feeding, Carbamazepine, Child, Epilepsy, Female, Humans, Pregnancy, Pregnancy Complications, Prenatal Exposure Delayed Effects, Triazines, Valproic Acid, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2017-017248
The paper
Veroniki, A. A., Rios, P., Cogo, E., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., Hemmelgarn, B. R., Yazdi, F., D'Souza, J., MacDonald, H., & Tricco, A. C. (2017). Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2017-017248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.